Glycotex Initiates Enrollment in Phase IIb Study of Topical Wound Healing Gel
Posted on: Wednesday, 22 October 2008, 09:00 CDT
Glycotex, a development stage biopharmaceutical company, has started enrollment of the first patient in a Phase IIb study evaluating the effect of GLYC-101 on wound closure and cosmetic outcomes in cosmetic surgery patients undergoing carbon dioxide laser skin resurfacing on the lower eyelid area.
The current randomized, double-blind, placebo-controlled clinical study will enroll approximately 48 patients at one clinical trial site in Beverly Hills, California.
Patients will be randomized to receive either GLYC-101 0.1% or GLYC-101 1% gel on one lower eyelid, and placebo on the other lower eyelid applied topically to the laser-ablated area immediately following the laser procedure and for four consecutive days thereafter.
The primary efficacy endpoint of the study is time to wound healing, and the secondary efficacy point is cosmetic outcomes, including scarring. The study will observe the effects of the topical agent over the course of one month following the initial treatment with the investigational compound and placebo.
Source: Datamonitor
Related Articles
- Data from Phase 2 Study of Peramivir in Patients Hospitalized with Influenza Presented at the XI International Symposium on Respiratory Viral Infections
- Study Results: Multiple Sclerosis Patients Have Significant and Sustained Reduction in Disability and Risk Of Relapse On Alemtuzumab Versus Approved Therapy, Rebif(R)
- Pediatrix Revises Earnings Guidance Reflecting Lower NICU Patient Volume
- Wyeth and Progenics Initiate New Clinical Studies to Investigate Additional Patient Populations for Methylnaltrexone
- Actelion Announces Successful Study With Tracleer(R) in Patients With Mildly Symptomatic Pulmonary Arterial Hypertension
- Tranzyme Pharma Expands Clinical Program of Its Novel Ghrelin Agonist, TZP-101, to Include Patients With Gastroparesis
- Clinically Significant Incidental Findings on the Unenhanced CT Portion of PET/CT Studies: Frequency in 250 Patients
- Study of Breast Cancer Patients Showed Regimen Including EMEND-R- -Aprepitant- Prevented Nausea and Vomiting After Chemotherapy in More Patients Than a Standard Regimen
- Nabi Biopharmaceuticals Announces Initiation of New StaphVAX(R) Immunogenicity Study in Orthopedic Surgery Patients
- Study: Caesarean Lowers Incontinence Risk
 |
 |
User Comments (0)
RSS Feeds